Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) shares rose 490% on Monday . The stock traded as high as $0.59 and last traded at $0.59. Approximately 100 shares were traded during trading, a decline of 90% from the average session volume of 959 shares. The stock had previously closed at $0.10.
Orgenesis Stock Up 490.0%
The stock has a fifty day moving average of $0.31 and a 200-day moving average of $0.39. The stock has a market cap of $3.05 million, a PE ratio of -0.05 and a beta of 3.22.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Further Reading
- Five stocks we like better than Orgenesis
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
